Results 81 to 90 of about 12,722 (192)

Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. [PDF]

, 2019
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Agewall, S, Rosano, GM, Spoletini, I, Vitale, C   +3 more
core   +2 more sources

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry

International Journal of Cardiology: Heart & Vasculature, 2020
Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function
Michele Correale, Adriana Mallardi, Pietro Mazzeo, Lucia Tricarico, Claudia Diella, Valentina Romano, Armando Ferraretti, Alessandra Leopizzi, Giuseppina Merolla, Matteo Di Biase, Natale Daniele Brunetti   +10 more
doaj   +1 more source

Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]

, 2019
The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio, Marchitti, Simona, Rubattu, Speranza, Volpe, Massimo   +3 more
core   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
], Akshay S. Desai, Barry M. Massie, Claudio Borghi, for the ATMOSPHERE Committees Investigators [, Georgia Tarnesby, Henry Krum, John J.V. McMurray, Kenneth Dickstein, Lars V. Køber, M. Atif Ali, Nicola Greenlaw, Qing Shao, Scott D. Solomon, William T. Abraham, Yanntong Chiang   +15 more
core   +5 more sources

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. [PDF]

, 2017
Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ( guided therapy ) with inconsistent ...
Adams, Kirkwood F., Anstrom, Kevin J., Cooper, Lawton S., Desvigne-Nickens, Patrice, Ezekowitz, Justin A, Felker, G. Michael, Fiuzat, Mona, Houston-Miller, Nancy, Januzzi, James L., Leifer, Eric S., Mark, Daniel B., O\u27Connor, Christopher M, Passmore, Gayle, Piña, Ileana L., Whellan, David J., Yang, Hongqiu   +15 more
core   +3 more sources

Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction

, 2016
Importance  The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.
Chan, Wing W., Claggett, Brian, Deschaseaux-Voinet, Celine, Fonarow, Gregg C., Gaziano, Thomas A., McMurray, John J.V., Rouleau, Jean L., Solomon, Scott D., Turner, Stuart J., Zile, Michael R.   +9 more
core   +1 more source

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source